[go: up one dir, main page]

NO971951L - Farmasöytiske preparater - Google Patents

Farmasöytiske preparater

Info

Publication number
NO971951L
NO971951L NO971951A NO971951A NO971951L NO 971951 L NO971951 L NO 971951L NO 971951 A NO971951 A NO 971951A NO 971951 A NO971951 A NO 971951A NO 971951 L NO971951 L NO 971951L
Authority
NO
Norway
Prior art keywords
provides
macrolide
class
compound
pharmaceutical composition
Prior art date
Application number
NO971951A
Other languages
English (en)
Other versions
NO316963B1 (no
NO971951D0 (no
Inventor
Martin Jackman
Xue-Ping Popp
Friedrich Richter
Fritz Schmook
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO971951(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9421612A external-priority patent/GB9421612D0/en
Priority claimed from GB9422306A external-priority patent/GB9422306D0/en
Priority claimed from GBGB9503553.1A external-priority patent/GB9503553D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO971951L publication Critical patent/NO971951L/no
Publication of NO971951D0 publication Critical patent/NO971951D0/no
Publication of NO316963B1 publication Critical patent/NO316963B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ppfinnelsen tilveiebringer et topisk preparat i form av en emulsjon som omfatter en forbindelse av FK506 klassen, en fysiologisk tålbar alkandiol, eterdiol eller dieteralkohol inneholdende opp til 8 karbonatomer som løsningsmiddel for forbindelsen av FK506 klassen, en umettet fettalkohol og vann. I et ytterligere aspekt tilveiebringer oppfinnelsen et topisk farmasøytisk preparat som omfatter et makrolid i suspensjon. I et annet aspekt tilveiebringer oppfinnelsen anvendelse av en umettet fettalkohol for å stabilisere et makrolid i et farmasøytisk preparat.
NO19971951A 1994-10-26 1997-04-25 Anvendelse av en umettet fettalkohol for a stabilisere et makrolid i et farmasoytisk preparat, samt et topisk preparat NO316963B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9421612A GB9421612D0 (en) 1994-10-26 1994-10-26 Organic compounds
GB9422306A GB9422306D0 (en) 1994-11-04 1994-11-04 Organic compounds
GBGB9503553.1A GB9503553D0 (en) 1995-02-22 1995-02-22 Organic compounds
PCT/EP1995/004208 WO1996013249A1 (en) 1994-10-26 1995-10-26 Pharmaceutical compositions

Publications (3)

Publication Number Publication Date
NO971951L true NO971951L (no) 1997-04-25
NO971951D0 NO971951D0 (no) 1997-04-25
NO316963B1 NO316963B1 (no) 2004-07-12

Family

ID=27267447

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19971951A NO316963B1 (no) 1994-10-26 1997-04-25 Anvendelse av en umettet fettalkohol for a stabilisere et makrolid i et farmasoytisk preparat, samt et topisk preparat
NO2004005C NO2004005I2 (no) 1994-10-26 2004-09-08 Pimecrolimus

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2004005C NO2004005I2 (no) 1994-10-26 2004-09-08 Pimecrolimus

Country Status (26)

Country Link
US (1) US6352998B2 (no)
EP (2) EP1147766B1 (no)
JP (3) JP4155593B2 (no)
KR (1) KR100434682B1 (no)
CN (2) CN100335063C (no)
AT (2) ATE214593T1 (no)
AU (1) AU714254B2 (no)
BR (1) BR9509530A (no)
CA (1) CA2200966C (no)
CY (1) CY2211B1 (no)
CZ (1) CZ289773B6 (no)
DE (3) DE69525957T2 (no)
DK (2) DK1147766T3 (no)
ES (2) ES2173978T3 (no)
FI (2) FI119754B (no)
GB (1) GB2308546B (no)
HK (1) HK1053611A1 (no)
HU (1) HU223840B1 (no)
MX (1) MX9702699A (no)
NO (2) NO316963B1 (no)
NZ (2) NZ295170A (no)
PL (1) PL184750B1 (no)
PT (2) PT1147766E (no)
SI (1) SI0786986T1 (no)
SK (1) SK284591B6 (no)
WO (1) WO1996013249A1 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CZ267796A3 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
DE19744621A1 (de) * 1997-10-09 1999-04-15 Muehlbauer Ernst Kg Mischung zur Verwendung als Wundverband
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE19802205A1 (de) * 1998-01-22 1999-07-29 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen, enthaltend erhöhte Elektrolytkonzentrationen
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
NZ507345A (en) * 1998-04-27 2002-12-20 Fujisawa Pharmaceutical Co Medicinal compositions
GB9814640D0 (en) * 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
NZ540000A (en) * 2001-02-16 2007-05-31 Abbott Lab Vascular Entpr Ltd Implants with tacrolimus
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
AU2004212264B9 (en) * 2003-02-17 2009-11-26 Cipla Limited Pharmaceutical patch
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
WO2005009436A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible formulation of an anti-inflammatory agent
DK1734927T3 (da) * 2004-04-08 2012-09-24 Meda Pharma S A R L Pimecrolimusskumsammensætning indeholdende hexylenglycol, eventuelt oleylalkohol, dimethylisosorbid og/eller middelkædede triglycerider
GB0408070D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Pharmaceutical formulations
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
WO2008063563A2 (en) 2006-11-16 2008-05-29 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mtor inhibitors
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
JP6084579B2 (ja) * 2012-01-25 2017-02-22 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
ES2797376T3 (es) * 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
MX367121B (es) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Composición sólida estable de inmunosupresores.
DE102013222164A1 (de) * 2013-10-31 2015-04-30 Deb Ip Limited Stabilisierte multiple Emulsionen als Hautschutzprodukt
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途
ES2985068T3 (es) * 2016-04-04 2024-11-04 Mc2 Therapeutics Ltd Composición tópica que comprende tacrolimus
IL267869B2 (en) 2017-01-06 2023-10-01 Palvella Therapeutics Inc Anhydrous compositions of mtor inhibitors and methods of use
KR101973065B1 (ko) 2017-09-13 2019-04-26 (주)썬테크 풍력 발전기 및 풍력 발전기의 블레이드 팁
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
KR101995905B1 (ko) 2018-03-27 2019-07-04 (주)썬테크 풍력 발전기 및 풍력 발전기의 발전모터
WO2019233722A1 (en) * 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
WO2024213629A1 (en) * 2023-04-11 2024-10-17 Bausch Health Ireland Limited Topical compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
DK175235B1 (da) 1987-11-09 2004-07-19 Novartis Ag Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf
EP0323042A1 (en) 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
ATE126803T1 (de) * 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
US5061700A (en) 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles
WO1991013899A1 (en) 1990-03-12 1991-09-19 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds
WO1991019495A1 (en) 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
ATE150304T1 (de) * 1990-09-04 1997-04-15 Fujisawa Pharmaceutical Co Tricyclische verbindungen enthaltende salben
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
IE65341B1 (en) 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
JP3644543B2 (ja) 1993-10-22 2005-04-27 ヘクサル・アーゲー シクロスポリンＡ及びα−トコフェロールを含有する医薬組成物

Also Published As

Publication number Publication date
SK284591B6 (sk) 2005-07-01
EP0786986A1 (en) 1997-08-06
HUT77140A (hu) 1998-03-02
AU714254B2 (en) 1999-12-23
US6352998B2 (en) 2002-03-05
DE69525957D1 (de) 2002-04-25
NO2004005I1 (no) 2004-09-20
SI0786986T1 (en) 2002-06-30
FI119754B (fi) 2009-03-13
WO1996013249A1 (en) 1996-05-09
NZ295170A (en) 1999-02-25
SK52097A3 (en) 1997-09-10
US20010031769A1 (en) 2001-10-18
CN1401325A (zh) 2003-03-12
JP2007145860A (ja) 2007-06-14
KR100434682B1 (ko) 2004-08-18
CN1089233C (zh) 2002-08-21
NO316963B1 (no) 2004-07-12
FI20071025L (fi) 2007-12-28
ATE214593T1 (de) 2002-04-15
BR9509530A (pt) 1997-10-14
GB9707484D0 (en) 1997-05-28
ES2243369T3 (es) 2005-12-01
JPH10508588A (ja) 1998-08-25
DE69534306D1 (de) 2005-08-11
EP1147766B1 (en) 2005-07-06
EP0786986B1 (en) 2002-03-20
FI971018L (fi) 1997-04-18
JP5599422B2 (ja) 2014-10-01
ATE299017T1 (de) 2005-07-15
PL319599A1 (en) 1997-08-18
CA2200966A1 (en) 1996-05-09
AU3845195A (en) 1996-05-23
CA2200966C (en) 2006-12-19
PT1147766E (pt) 2005-11-30
KR970706796A (ko) 1997-12-01
CN1162259A (zh) 1997-10-15
CY2211B1 (en) 2002-11-08
CZ123297A3 (en) 1997-08-13
FI119755B (fi) 2009-03-13
FI971018A0 (fi) 1997-03-11
GB2308546A (en) 1997-07-02
EP1147766A3 (en) 2001-10-31
HK1053611A1 (en) 2003-10-31
HU223840B1 (hu) 2005-02-28
ES2173978T3 (es) 2002-11-01
DE19581804T1 (de) 1998-01-22
NO2004005I2 (no) 2007-06-11
CN100335063C (zh) 2007-09-05
DK1147766T3 (da) 2005-08-29
CZ289773B6 (cs) 2002-04-17
JP2012131827A (ja) 2012-07-12
JP4155593B2 (ja) 2008-09-24
NO971951D0 (no) 1997-04-25
DE69534306T2 (de) 2006-04-27
PL184750B1 (pl) 2002-12-31
GB2308546B (en) 1999-06-02
DK0786986T3 (da) 2002-04-29
EP1147766A2 (en) 2001-10-24
PT786986E (pt) 2002-07-31
NZ331824A (en) 2000-01-28
MX9702699A (es) 1997-06-28
DE69525957T2 (de) 2002-11-14

Similar Documents

Publication Publication Date Title
NO971951L (no) Farmasöytiske preparater
AR004483A1 (es) Compuestos para uso en terapia que comprenden un residuo de 1,3-propano diol como agente enlazante entre el residuo de ácido graso y un residuo bioactivo, usos de dichos compuestos y medicamentos , alimentos y formulaciones para el cuidado o tratamiento de la piel que comprenden a dichos compuestos
KR890701090A (ko) 뽕나무의 추출물을 함유하는 조성물
CA2173104A1 (en) Non-sweating lipsticks
CA2302554A1 (en) Oil in water emulsions containing saponins
CA2288694A1 (en) Active vitamin d3 emulsion lotion
AU2960497A (en) Process for producing a paraffin-based object and such an object
AU669122B2 (en) New pyrazine derivatives, their preparation and their use
ES2171889T3 (es) Agente que reduce el colesterol en suero.
DK0734257T3 (da) Farmaceutiske præparater til topisk anvendelse, der indeholder (S)-2-(4-isobutylphenyl)propionsyre
AR012546A1 (es) Utilizacion de al menos un compuesto seleccionado entre el grupo que comprende los sogaoles y los gingeroles para la preparacion de una composiciondesodorante, sogaol, extracto bruto y extracto purificado que contiene el sogaol y la composicion desodorante obtenida.
NO971417L (no) Nye estrener for indusering av hypotalmiske effekter
CA2271268A1 (en) Therapeutic and cosmetic compositions comprising an extract of crude shark liver oil, their use and method for the preparation thereof
JPH07309712A (ja) 皮膚化粧料
ATE42743T1 (de) Thiochromanderivat, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
JPS62289520A (ja) エリスロマイシン塩基含有抗アクネ安定組成物
GB9421612D0 (en) Organic compounds
JPS6425709A (en) Skin cosmetic for clean room

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: ELIDEL KREM 1%; NAT. REG. NO/DATE: MT02-1563 20030430; FIRST REG. NO/DATE: DK , 21034 20020315

Spc suppl protection certif: 2004005

Filing date: 20040908

Extension date: 20170315

MM1K Lapsed by not paying the annual fees
RE Reestablishment of rights (par. 72 patents act)
MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2004005